28 results
424B5
VERV
Verve Therapeutics Inc
29 Nov 23
Prospectus supplement for primary offering
4:47pm
and interest rates, on our business, operations, strategy and goals.
We may not actually achieve the plans, intentions or expectations disclosed
424B5
VERV
Verve Therapeutics Inc
28 Nov 23
Prospectus supplement for primary offering
4:25pm
the COVID-19 pandemic, and of global economic developments, including rising inflation and interest rates, on our business, operations, strategy and goals
DEF 14A
4h3keco6f6gv uqctake
29 Apr 22
Definitive proxy
7:01am
10-K
r7i5d7doqktkdv
14 Mar 22
Annual report
7:04am
8-K
EX-99.1
dunpsjg
14 Mar 22
Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2021 Financial Results
6:49am
10-Q
ccninv3
12 Aug 21
Quarterly report
8:53am
424B4
vrd6pvrd4i
17 Jun 21
Prospectus supplement with pricing info
4:50pm
S-1/A
a805tq up14i2lyge4
14 Jun 21
IPO registration (amended)
6:15am